Comorbidity of type 2 diabetes mellitus and diffused non-toxic goiter: laboratory data

Abstract

Summary. The prevalence of type 2 diabetes and diffuse non-toxic goiter increases worldwide. It has been reported that patients with impaired glucose metabolism have larger thyroid volumes. The researchers have increasingly focused on studying the relationship between insulin resistance and abnormal thyroid function and morphology. The aim of the study – to evaluate laboratory data in patients with comorbidity of type 2 diabetes mellitus and diffuse non-toxic goiter and identify possible markers of their comorbid course. Materials and Methods. The study included medical records of 541 patients. Two experimental groups were formed: 40 patients with diffuse non-toxic goiter and type 2 diabetes mellitus and 501 patients with type 2 diabetes only. Each patient had ultrasound examination of thyroid gland. The size of thyroid gland was calculated by the Bruno method. Data of lipid profile, general blood analysis, level of insulin, glucose, biochemical blood analysis, thyroid hormones (TSH, T4) were defined. Statistical analysis was performed by calculating the median (Me), lower (Lq) and upper (Uq) quartiles, Mann-Whitney U-test. Results. The average age of patients was 56 years. General blood analysis had significantly higher ESR levels by 63.6 % in the group of T2D + diffuse non-toxic goiter in comparison with T2D. Significantly higher levels of HbA1c by 7.4 %, non-HDL-C by 3.57 % in the group T2D + diffuse non-toxic goiter in comparison with T2D. Conclusions. Patients with combined type 2 diabetes mellitus and diffuse non-toxic goiter have significantly higher levels of ESR, HbA1c, and progressive dyslipidemia due to non-HDL-C, compared with patients with type 2 diabetes mellitus only. There is a tendency to increase total and residual cholesterol in the group of T2D + diffuse non-toxic goiter compared with T2D

Keywords

• type 2 diabetes mellitus
• diffuse non-toxic goiter
• comorbidity
• laboratory data